Testosterone: A Review for Orthopaedic Surgeons.
Journal
JBJS reviews
ISSN: 2329-9185
Titre abrégé: JBJS Rev
Pays: United States
ID NLM: 101674872
Informations de publication
Date de publication:
01 Jun 2024
01 Jun 2024
Historique:
medline:
18
6
2024
pubmed:
18
6
2024
entrez:
18
6
2024
Statut:
epublish
Résumé
» Testosterone replacement treatment (TRT) and anabolic androgenic steroid (AAS) use is common and possibly increasing.» Diagnosing and treating hypogonadism in men is controversial.» Hypogonadism and the use of AASs seem to have a detrimental effect on the musculoskeletal system. The current literature on TRT and the musculoskeletal system shows an increased risk of tendon injury.» There may be a role for testosterone supplementation in the postoperative period.
Identifiants
pubmed: 38889232
doi: 10.2106/JBJS.RVW.24.00061
pii: 01874474-202406000-00005
doi:
Substances chimiques
Testosterone
3XMK78S47O
Androgens
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 by The Journal of Bone and Joint Surgery, Incorporated.
Déclaration de conflit d'intérêts
Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article (http://links.lww.com/JBJSREV/B110).
Références
Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173(15):1465-6.
Layton JB, Li D, Meier CR, Sharpless JL, Stürmer T, Jick SS, Brookhart MA. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab. 2014;99(3):835-42.
Tsametis CP, Isidori AM. Testosterone replacement therapy: for whom, when and how? Metabolism. 2018;86:69-78.
Diokno AC. The role of testosterone in men's health: is it time for a new approach? Int Urol Nephrol. 2022;54(11):2767-74.
Yeo S, Holl K, Peñaherrera N, Wissinger U, Anstee K, Wyn R. Burden of male hypogonadism and major comorbidities, and the clinical, economic, and humanistic benefits of testosterone therapy: a narrative review. Clinicoecon Outcomes Res. 2021;13:31-8.
Bond P, Smit DL, de Ronde W. Anabolic-androgenic steroids: how do they work and what are the risks? Front Endocrinol. 2022;13:1059473.
Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997;82(2):407-13.
Granados J, Gillum TL, Christmas KM, Kuennen MR. Prohormone supplement 3β-hydroxy-5α-androst-1-en-17-one enhances resistance training gains but impairs user health. J Appl Physiol (1985). 2014;116(5):560-9.
Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, Dzekov J, Magliano L, Storer TW. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005;90(2):678-88.
Smit DL, Buijs MM, de Hon O, den Heijer M, de Ronde W. Positive and negative side effects of androgen abuse. The HAARLEM study: a one-year prospective cohort study in 100 men. Scand J Med Sci Sports. 2021;31(2):427-38.
Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. 2014;24(5):383-98.
Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724-31.
Morley JE, Perry HM, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas. 2006;53(4):424-9.
Barbonetti A, D'Andrea S, Francavilla S. Testosterone replacement therapy. Andrology. 2020;8(6):1551-66.
Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E, Wang PY, Nielson C, Wu F, Tajar A, Labrie F, Vesper H, Zhang A, Ulloor J, Singh R, D'Agostino R, Vasan RS. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96(8):2430-9.
Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM; Task Force Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-59.
Buvat J, Maggi M, Gooren L, Guay AT, Kaufman J, Morgentaler A, Schulman C, Tan HM, Torres LO, Yassin A, Zitzmann M. Endocrine aspects of male sexual dysfunctions. J Sex Med. 2010;7(4 pt 2):1627-56.
Defeudis G, Mazzilli R, Gianfrilli D, Lenzi A, Isidori AM. The CATCH checklist to investigate adult-onset hypogonadism. Andrology. 2018;6(5):665-79.
Rivero MJ, Reddy R, Muthigi A, Reddy R, Han S, Reis IM, Patel M, Ramasamy R. Patient satisfaction with oral testosterone undecanoate in men who received prior testosterone therapy: an open-label, single-center clinical trial. World J Mens Health. 2024;42:e16.
Isidori AM, Balercia G, Calogero AE, Corona G, Ferlin A, Francavilla S, Santi D, Maggi M. Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian Society of Endocrinology. J Endocrinol Invest. 2015;38(1):103-12.
Huo S, Scialli AR, McGarvey S, Hill E, Tügertimur B, Hogenmiller A, Hirsch AI, Fugh-Berman A. Treatment of men for ‘low testosterone’: a systematic review. PLoS One. 2016;11(9):e0162480.
Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N; Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2839-53.
Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335(1):1-7.
Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA, Ensrud KE, Lewis CE, Barrett-Connor E, Schwartz AV, Lee DC, Bhasin S, Cunningham GR, Gill TM, Matsumoto AM, Swerdloff RS, Basaria S, Diem SJ, Wang C, Hou X, Cifelli D, Dougar D, Zeldow B, Bauer DC, Keaveny TM. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med. 2017;177(4):471-9.
Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, Saad F, Mannucci E, Maggi M. Therapy of endocrine disease: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174(3):R99-116.
Amanatkar HR, Chibnall JT, Seo BW, Manepalli JN, Grossberg GT. Impact of exogenous testosterone on mood: a systematic review and meta-analysis of randomized placebo-controlled trials. Ann Clin Psychiatry. 2014;26(1):19-32.
Tong SF, Ng CJ, Lee BC, Lee VKM, Khoo EM, Lee EG, Tan HM. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian J Androl. 2012;14(4):604-11.
Traish AM, Haider A, Haider KS, Doros G, Saad F. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (control) groups. J Cardiovasc Pharmacol Ther. 2017;22(5):414-33.
Porcaro AB, Cerrato C, Tafuri A, Bianchi A, Gallina S, Orlando R, Amigoni N, Rizzetto R, Gozzo A, Migliorini F, Zecchini Antoniolli S, Monaco C, Brunelli M, Cerruto MA, Antonelli A. Low endogenous testosterone levels are associated with the extend of lymphnodal invasion at radical prostatectomy and extended pelvic lymph node dissection. Int Urol Nephrol. 2021;53(10):2027-39.
Mearini L, Zucchi A, Nunzi E, Villirillo T, Bini V, Porena M. Low serum testosterone levels are predictive of prostate cancer. World J Urol. 2013;31(2):247-52.
Cook MB, Beachler DC, Parlett LE, Cochetti PT, Finkle WD, Lanes S, Hoover RN. Testosterone therapy in relation to prostate cancer in a U.S. commercial insurance claims database. Cancer Epidemiol Biomarkers Prevent. 2020;29(1):236-45.
Saad F, Caliber M, Doros G, Haider KS, Haider A. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. Aging Male. 2020;23(1):81-92.
Warburton D, Hobaugh C, Wang G, Lin H, Wang R. Testosterone replacement therapy and the risk of prostate cancer. Asian J Androl. 2015;17(6):878-81; discussion 880.
Kang DY, Li HJ. The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94(3):e410.
Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FCW. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008;159(5):507-14.
Medras M, Filus A, Jozkow P, Winowski J, Sicinska-Werner T. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res Treat. 2006;96(3):263-5.
Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.
Martinez C, Suissa S, Rietbrock S, Katholing A, Freedman B, Cohen AT, Handelsman DJ. Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ. 2016;355:i5968.
Smith KM, Hotaling JM, Presson AP, Zhang C, Horns JJ, Cannon-Albright LA, Teerlink CC, Tashjian RZ, Chalmers PN. The effect of sex hormone deficiency on the incidence of rotator cuff repair: analysis of a large insurance database. J Bone Joint Surg Am. 2022;104(9):774-9.
Testa EJ, Albright JA, Hartnett D, Lemme NJ, Daniels AH, Owens BD, Arcand M. The relationship between testosterone therapy and rotator cuff tears, repairs, and revision repairs. J Am Acad Orthop Surg. 2023;31(11):581-8.
Rebello E, Albright JA, Testa EJ, Alsoof D, Daniels AH, Arcand M. The use of prescription testosterone is associated with an increased likelihood of experiencing a distal biceps tendon injury and subsequently requiring surgical repair. J Shoulder Elbow Surg. 2023;32(6):1254-61.
Albright JA, Lou M, Rebello E, Ge J, Testa EJ, Daniels AH, Arcand M. Testosterone replacement therapy is associated with increased odds of achilles tendon injury and subsequent surgery: a matched retrospective analysis. J Foot Ankle Res. 2023;16(1):76.
Meghani O, Albright JA, Testa EJ, Arcand MA, Daniels AH, Owens BD. Testosterone therapy is associated with increased odds of quadriceps tendon injury. Clin Orthop Relat Res. 2023;482(1):175-81.
Thompson K, Klein D, Sreekumar S, Kenny L, Campbell K, Alaia M, Strauss EJ, Jazrawi L, Gonzalez-Lomas G. Testosterone levels before and after anterior cruciate ligament reconstruction: a prospective observational study. Bull Hosp Jt Dis (2013). 2022;80(3):265-9.
Tashjian RZ, Zitnay J, Kazmers NH, Veerabhadraiah SR, Zelada AC, Honeggar M, Chalmers PN, Henninger HB, Jurynec MJ. Estrogen and testosterone supplementation improves tendon healing and functional recovery after rotator cuff repair. J Orthop Res. 2024;42(2):259-66.